An in-depth look at the clinical trial data for AEF0117, a novel CB1 receptor signaling-specific inhibitor, and its implications for treating Cannabis Use Disorder (CUD). Presented by NINGBO INNO PHARMCHEM CO.,LTD., this analysis covers Phase 1 and 2a results.
